Eatontown, NJ, April, 1 2016. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Ethosuximide 250mg soft gelatin capsules. This launch adds to Avet’s robust portfolio of generic oral solid products.
Ethosuximide is the AB rated generic equivalent to the antiepileptic drug Zarontin®*. It is indicated for the control of absence (petit mal) epilepsy. According to IMS data for the twelve-months ended February 2016, the U.S. market for Ethosuximide 250mg soft gelatin capsules is approximately $15 million.